Here's the complete summary:
UCLA holds several dendritic cell vaccine patents that, according to available data, are not licensed to Northwest Biotherapeutics (NWBO) for commercial use. These patents pertain to novel methods, combinations, and recombinant engineering outside the primary DCVax/aDC1 platform exclusively licensed to NWBO. The main patent families not licensed to NWBO include:
US20150202291A1: Covers combinations of checkpoint inhibitors and dendritic cell vaccines for cancer treatment, primarily pending and associated with UCLA researchers. This is often mentioned as UCLA Case No. 2015-341 in clinical publications and conflict-of-interest disclosures.
US11413338B2: Methods and compositions using recombinant dendritic cells for cancer therapy, focused on genetic engineering rather than DCVax-like platforms.
EP1565196A1: Clinical application of dendritic cell-based cancer immunotherapy, reporting broad methods distinct from DCVax/aDC1 IP.
These patents allow UCLA to pursue academic research, clinical trials, and certain commercial applications independent of NWBO, as long as they do not utilize the processes or technology covered under NWBO's exclusive aDC1/DCVax maturation and manufacturing rights. This provides pathways for innovative vaccine combinations and novel cell engineering distinct from NWBO’s portfolio.
Source: Perplexity AI
Market Data 
Markets 
AI
